ProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary

ProQR Therapeutics NV

13/08/2026 14:31

ProQR Therapeutics NV PRQR.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of seven analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -16 cents to -7 cents per share.
Revenue rose 129.5% to €8.76 million from a year ago; analysts expected €4.58 million. 
ProQR Therapeutics NV's reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of €8.68 million.
ProQR Therapeutics NV shares had held steady so far this quarter and lost 7.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 7.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 79.3% above its last closing price of $1.86
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.11
-0.08
Beat
Mar. 31 2026 
-0.12
-0.13
Missed
Dec. 31 2025 
-0.10
-0.08
Beat
Sep. 30 2025 
-0.10
-0.10
Met